Pfizer Inc. (NYSE:PFE) ranks among the best low-risk investments in May 2026. On April 13, Guggenheim reaffirmed a Buy rating and a $36 price target for Pfizer Inc. (NYSE:PFE) as the firm revised its ...
If you are wondering whether Pfizer's current share price properly reflects its long term potential, the recent share ...
Pfizer heads into earnings with a lower Goldman Sachs price target as investors weigh patent risks, Covid declines, and ...
Pfizer PFE is set to report its first-quarter 2026 earnings on May 5, before market open. The Zacks Consensus Estimate for ...
Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) are two pharmaceutical giants that seem to be headed in opposite directions.
Zacks Investment Research on MSN
Ahead of Pfizer (PFE) Q1 earnings: Get ready with Wall Street estimates for key metrics
Wall Street analysts expect Pfizer (PFE) to post quarterly earnings of $0.74 per share in its upcoming report, which indicates a year-over-year decline of 19.6%. Revenues are expected to be $13.82 ...
Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...
Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results